Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03231228 · ClinicalTrials.gov registry record · Phase 4
Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
A Phase 4 study, sponsored by B. Braun Medical.
- Terminated
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
NCT03231228: Clinical Trial Phase 4 study, sponsored by B. Braun Medical.
NCT03231228 is a Phase 4 study that was terminated before completion, run by B. Braun Medical. The registered enrollment target is 61 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03231228, a Phase 4 study, was terminated before completion, sponsored by B. Braun Medical.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
Study Summary
This is a Phase 4, open-label, single-dose, parallel-group, multicenter, safety study of cefazolin (1 g or 2 g) in pediatric subjects between 10 and 17 years of age (inclusive) scheduled for surgery.
Primary Outcome
Safety will be assessed by monitoring adverse events (AEs), physical examinations, vital signs, ECGs, and clinical laboratory results.
Interventions
- DRUG Cefazolin 1 g Infusion
- DRUG Cefazolin 2 g Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-11-20 |
| Est. Completion | 2019-07-31 |
| Phase | Phase 4 |
Why NCT03231228 stopped before completion
NCT03231228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Cefazolin 1 g Infusion is the first listed.
NCT03231228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03231228 about?
NCT03231228 is a clinical study titled "Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects". This is a Phase 4, open-label, single-dose, parallel-group, multicenter, safety study of cefazolin (1 g or 2 g) in pediatric subjects between 10 and 17 years of age (inclusive) scheduled for surgery.
What is the current status of trial NCT03231228?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2017-11-20. Estimated completion is 2019-07-31.
What interventions are being tested in trial NCT03231228?
The interventions under investigation include: Cefazolin 1 g Infusion (DRUG), Cefazolin 2 g Infusion (DRUG).
Who is sponsoring clinical trial NCT03231228?
This trial is sponsored by B. Braun Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03231228's enrollment target sits among peer trials
61 1119th of 2000 higher than 876 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI